

Special Issue

From Knowledge to Action: Advances in Herpes Zoster Vaccine and Vaccination

Message from the Guest Editors

Herpes zoster, also known as shingles, is a condition caused by the reactivation of the varicella zoster virus. Public knowledge about shingles and its vaccination is often limited, leading to misconceptions and underestimation of the disease's severity. Vaccine uptake is uneven, with disparities based on socioeconomic status, race, ethnicity, and geography due to limited access, financial barriers, and inconsistent healthcare recommendations. Two main vaccines are available: Shingrix (recombinant subunit) and Zostavax (live attenuated). The former is preferred for immunocompromised individuals, because it is a non-live vaccine, reducing the risks associated with live vaccines like Zostavax. Effective vaccine campaigns, vital for increasing herpes zoster vaccination rates, are starting globally. Strategies should focus on raising awareness about the disease and the vaccination benefits and addressing common misconceptions. Leveraging media platforms and engaging healthcare providers in proactive outreach are required to increase vaccination coverage.

Guest Editors

Dr. Giulia Silvestrini

Romagna Local Health Authority, Ravenna, Italy

Dr. Manuela Chiavarini

Department of Biomedical Sciences and Public Health, Section of Hygiene, Preventive Medicine and Public Health, Polytechnic University of the Marche Region, Ancona, Italy

Deadline for manuscript submissions

31 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/208971

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).